Heart disease prevention
You do not need every heart test. You need the one that answers the next decision.
Guides
How to Prevent Atherosclerosis: A First-Principles Guide to Lipids and Plaque
Preventing atherosclerosis means lowering cumulative ApoB particle exposure and controlling the forces that injure the artery wall. I would start with a standard lipid panel plus ApoB and one-time Lp(a), blood pressure, metabolic risks, kidney function, smoking, and family history, then use CAC or CCTA selectively only when the result changes treatment.
Is ApoB better than LDL?
Often, yes, especially when metabolic risk is present. LDL-C measures cholesterol mass inside LDL particles; ApoB better approximates the number of atherogenic particles that can enter and be retained in the artery wall. I still look at the standard lipid panel, but ApoB is the number I most want when the prevention decision is not obvious.
Do I need a coronary calcium scan?
Maybe. I use CAC as a tie-breaker for adults whose cardiovascular risk sits in the gray zone, where a real choice about statins or prevention intensity is still on the table. I would not order it for active chest pain, or use a zero score to wave away diabetes, smoking, very high LDL-C, or a family history of early heart disease.
Supplements That Lower LDL Cholesterol: What Works, What Doesn't, and What I Use Instead
Psyllium and food-based soluble fiber are reasonable adjuncts when the LDL or ApoB gap is small. When 30–50% or more lowering is needed, or cardiovascular risk is high, regulated therapy is usually more effective, predictable, and often safer than a supplement stack.
OmegaCheck and the Omega-6:Omega-3 Ratio
Start with the assay and the individual fatty acids. I want to know whether marine omega-3 is low, whether food or a supplement changed the result, and whether the test adds anything to the decision. I would not treat 4:1 as a universal target or cut nuts, seeds, and ordinary plant oils to lower the ratio.
Which Inflammation Test Do You Need? CRP, hsCRP, ESR, Ferritin, and More
Test choice depends on the clinical question. CRP can reflect systemic inflammatory activity, hsCRP can refine cardiovascular risk in selected stable adults, ESR is indirect, and ferritin belongs in an iron assessment. Inflammation is a biological process, not one substance or whole-body score. Ask what can move the result, whether sampling was stable, and what decision changes.
Testing
Episodes
High ApoB, CAC Zero: What Your Heart Tests Are Really Saying
Two confident, well-read people are arguing online. One says drive ApoB as low as humanly possible. The other says that if your insulin, triglycerides and blood pressure are good, your lipid panel is beside the point. Dr. Lin's argument is that this is not a disagreement about science — it is two people each holding one piece of the same puzzle.
I Treat Cholesterol Differently Now: Statins, PCSK9s, Ezetimibe & Gene Editing
Part three of the modern lipid playbook, and the one about treatment. Dr. Lin opens with her own case rather than a case study: a paternal family history of stroke, sudden cardiac arrest, aortic dissection and a heart transplant, and her own ApoB coming back at 128. What follows is an honest accounting of the full toolkit, from a $4 generic with more outcome data behind it than almost any drug in medicine, to a twice-yearly injection most patients have never heard of, to a base-editing therapy with published phase one data.
The Cholesterol You Can’t Diet Away: Lp(a) Explained
Lp(a) is the cardiovascular risk factor most likely to be high in someone with a perfectly normal lipid panel, and the one least likely to have been tested for. Dr. Lin opens with a patient whose father had a heart attack at 52 and whose own cholesterol always came back normal — the answer only appeared once Lp(a) was measured.
The Drug Lowered Lp(a). So Why Didn't the Trial Prove a Heart Benefit?
My patient hiked, lifted weights, and watched what he ate. He still needed a heart stent.
My LDL Was 192. Then I Found the First PCSK9 Pill.
My LDL was 192 even though I felt healthy. That result sent me into the story of PCSK9—a protein discovered outside cholesterol research that became the target of injections, RNA silencing, the first oral PCSK9 inhibitor, and now one-time gene-editing experiments.
The Modern Lipid Playbook Part 2: THE TESTING — Why Your Lipid Panel Isn't Enough
David was 62, exercised, ate well, saw his doctor every year, and had an LDL in the 40s — below even aggressive targets. He had been told he was fine for 25 years. When Dr. Lin ordered the tests nobody had run, his widowmaker artery was 75–99% blocked and his calcium score was 1,522, nearly four times the threshold for severe.
The Heart Attack You Won't See Coming (Even With 'Good' Stats).
In a single year in her early thirties, Dr. Lin watched atherosclerosis move through her family: her grandmother died of a heart attack in her sleep in Taiwan on a night the air conditioning failed, her aunt of aortic dissection, her grandfather of a stroke, and her father survived a cardiac event catastrophic enough to require a mechanical heart and then a full transplant. Those sound like four diseases. Her first argument is that they are one — the same pathology at four addresses in a vascular system that runs everywhere.
The "Normal" Cholesterol Myth: Detecting the Widowmaker Before It Strikes
Dr. John Osborne is a preventive cardiologist and clinical lipidologist in Dallas–Fort Worth, with an MD and PhD in cardiovascular physiology, training at Harvard and Brigham and Women's, and board certification in both cardiovascular disease and clinical lipidology — a combination roughly a hundred physicians in the country hold. He is also, by his own description, a rare bird: of about 33,000 US cardiologists, roughly 600 are preventive.
Not sure which heart test to ask about next? Get the free guide.